Adam Hochron

As new medications have been approved for movement disorders like Parkinson's Disease many patients have been able to better manage their symptoms. When that is not enough newer surgical options have also been developed in recent years.

Technology may be advancing faster than people can keep up with but there are still times when traditional surgical methods are preferred over newer technologies.

While minimally invasive surgery is not a new concept the rapid advances in technology are helping to treat patients with more wide ranging conditions than ever before.

For many, cardiovascular disease can be seen as mostly an issue facing men. However, work has been done to raise the education of women to help ensure their health as well.

While some people may see high blood pressure as a normal factor in pregnancy and delivery it can actually be a serious problem at the time and down the road.

There has been plenty of research to show that rehabilitation can help with the cognitive function of patients with multiple sclerosis. A recent study looked at whether advanced imaging can determine whether some patients will respond better to the therapy than others.

Depending on the age of the children they are treating pediatricians have to find a good working relationship with parents while also maintaining the privacy of their patients.

In adult patients neuromyelitis optica is considered a rare enough condition. It is even more rare in children making the diagnosis and treatment a longer and more careful process.

There are now more than a dozen medications approved for the treatment of relapsing multiple sclerosis, a treatment pending approval for primary progressive, and very early signs of hope for secondary progressive. As a result there was plenty of optimism at ECTRIMS as it left London and prepared for Paris next year.

As Ocrelizumab moves its way through the approval process for patients with primary progressive multiple sclerosis, data has been released on a trial for a potential treatment for the secondary progressive form.

There is no longer any question about the health risks associated with smoking. What remains to be found is what is the best way to help people who have started to smoke to quit.

As the effort continues to help people quit smoking research is being done to find the best treatment options available and any potential issues they may present in the process.

As the annual ECTRIMS conference in London wound down there was definitely a sense of optimism that there would be more good news to come before the group meets next October in Paris.

When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.

At the moment the best way to get a diagnosis of multiple sclerosis is through a brain scan. A team in Tennessee is working to improve that with a blood test that could find the condition sooner allowing for treatment to begin faster.

As the leading minds in the field of multiple sclerosis came together in London for the annual ECTRIMS conference the end of the conference brought a considerable amount of excitement in everything from the relapsing form to progressive forms.

As more and more treatments are approved for patients with multiple sclerosis questions are being answered about their effectiveness long past their approval dates. This is true for many of the medications including lemtrada.

While neurologists may be able to successfully diagnose progressive multifocal leukoencephalopathy it may take a more specialized health care professional to effectively treat the condition.

Progressive multifocal leukoencephalopathy, also known as PML is a problem which can affect a select number of patients with multiple sclerosis as well as other conditions which involve the immune system. What can be done to address the condition is still being determined by the medical community.

Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.

There are currently no medications approved for the treatment of neuromyelitis optica. However, there are clinical trials underway and more research being done to change that in the coming years.

With multiple medications approved to treat multiple sclerosis there is more work being done to help a larger patient population through the course of disease treatment.

It has been a few years now since Tecfidera was approved by the US Food and Drug Administration. In that time there has bee continued research which has shown positive results for patients.

Having been recently approved for patients with the relapsing form of multiple sclerosis more data is being done to show ways it can help manage symptoms while also being a safe option.

The treatment of multiple sclerosis has come a long way in recent years. However, there is a lot more to be done. There is optimism that over time treatment can be even more effective and help even more patients as new treatment methods are developed.

Patients diagnosed with relapsing remitting multiple sclerosis have seen their treatment options increase dramatically in recent years. Now patients with the progressive forms are seeing the the start of momentum building in their favor.

Even while robotic surgery becomes more popular in urology, there are still conditions where open or laparoscopic procedures may still produce the best results, even while newer technology continues to be developed at a rapid pace.

As the field of robotic surgery becomes more specialized the number of locations where the procedures is also showing signs of decreasing. Even as technology continues to improve there are still concerns that not all patients who would benefit have it readily available.

As robotic surgery has become more popular in fields like urology and gynecology questions have been raised about who is most likely to undergo these procedures and why that is the case.

From the ventricular assist device and beyond the treatment of heart failure has made a considerable number of advancements. Even small steps like longer battery life and smaller devices can make a big difference in a patient's daily life going